Anthos Therapeutics, Inc.
Clinical trials sponsored by Anthos Therapeutics, Inc., explained in plain language.
-
New blood thinner tested for cancer clot prevention, study halted early
Disease control TerminatedThis study tested a new blood thinner, abelacimab, against a standard one (dalteparin) in 417 adults with gastrointestinal or genitourinary cancers who also had blood clots. The goal was to see which drug better prevented new clots and caused less bleeding. The trial was terminat…
Phase: PHASE3 • Sponsor: Anthos Therapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New blood thinner tested for cancer patients at risk of clots
Disease control TerminatedThis study tested a new blood thinner called abelacimab against the standard drug apixaban in about 1,150 people with cancer who had a blood clot (VTE). The goal was to see which drug better prevents new clots and causes less bleeding. The trial was stopped early, so final result…
Phase: PHASE3 • Sponsor: Anthos Therapeutics, Inc. • Aim: Disease control
Last updated May 20, 2026 11:57 UTC